secwatch.observer — SEC 8-K summary
======================================

Issuer:     Y-mAbs Therapeutics, Inc. (—)
CIK:        0001722964
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001558370-24-007047
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Y-mAbs reports Q1 2024: U.S. DANYELZA rev up 11% to $18.6M; net loss $0.15/share
--------------------------------------------------------------------------------

- U.S. DANYELZA net revenue $18.6M (+11% YoY); worldwide $19.4M (-4% YoY on international stocking shipment in Q1 2023).
- Net loss $6.6M ($0.15 per share), relatively flat vs Q1 2023 loss of $6.4M.
- Cash $75.7M, cash burn $2.9M in Q1; FY2024 guidance reaffirmed: rev $95-100M, cash runway into 2027.
- CFO Bo Kruse to resign upon successor appointment; search firm retained.
- Adium launched DANYELZA in Brazil/Mexico in April; five new U.S. accounts added in Q1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1722964/000155837024007047/0001558370-24-007047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1722964/000155837024007047/ymab-20240507x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-007047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer